Miglustat hydrochlorideGlycosyltransferase inhibitor; broad spectrum antiviral activity CAS# 210110-90-0 |
- Meprednisone
Catalog No.:BCC4893
CAS No.:1247-42-3
- Hydrocortisone
Catalog No.:BCN2192
CAS No.:50-23-7
- Prednisolone
Catalog No.:BCC4830
CAS No.:50-24-8
- Desonide
Catalog No.:BCC4967
CAS No.:638-94-8
- Fluticasone propionate
Catalog No.:BCC4907
CAS No.:80474-14-2
- Methylprednisolone
Catalog No.:BCC2256
CAS No.:83-43-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 210110-90-0 | SDF | Download SDF |
PubChem ID | 6603107 | Appearance | Powder |
Formula | C10H22ClNO4 | M.Wt | 255.74 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | <em>N</em>-Butyldeoxynojirimycin hydrochloride, NB-DNJ | ||
Solubility | H2O : ≥ 34 mg/mL (132.95 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride | ||
SMILES | CCCCN1CC(C(C(C1CO)O)O)O.Cl | ||
Standard InChIKey | QPAFAUYWVZMWPR-ZSOUGHPYSA-N | ||
Standard InChI | InChI=1S/C10H21NO4.ClH/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12;/h7-10,12-15H,2-6H2,1H3;1H/t7-,8+,9-,10-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Orally active α-glucosidase I and II and ceramide-specific glycosyltransferase inhibitor. Rescues trafficking-deficient F508del-CFTR in human airway epithelial cells via inhibition of ER α-glucosidases I and II. Also has broad spectrum antiviral activity. |
Miglustat hydrochloride Dilution Calculator
Miglustat hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.9102 mL | 19.5511 mL | 39.1022 mL | 78.2044 mL | 97.7555 mL |
5 mM | 0.782 mL | 3.9102 mL | 7.8204 mL | 15.6409 mL | 19.5511 mL |
10 mM | 0.391 mL | 1.9551 mL | 3.9102 mL | 7.8204 mL | 9.7756 mL |
50 mM | 0.0782 mL | 0.391 mL | 0.782 mL | 1.5641 mL | 1.9551 mL |
100 mM | 0.0391 mL | 0.1955 mL | 0.391 mL | 0.782 mL | 0.9776 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Miglustat Hhydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
- 5,8,9,10,14-Pentaacetoxy-3-benzoyloxy-15-hydroxypepluane
Catalog No.:BCN1498
CAS No.:210108-91-1
- Jatrophane VI
Catalog No.:BCN7659
CAS No.:210108-90-0
- Jatrophane 5
Catalog No.:BCN1499
CAS No.:210108-89-7
- Jatrophane 4
Catalog No.:BCN1500
CAS No.:210108-88-6
- Jatrophane 3
Catalog No.:BCN1501
CAS No.:210108-87-5
- Jatrophane 2
Catalog No.:BCN1502
CAS No.:210108-86-4
- Jatrophane I
Catalog No.:BCN7658
CAS No.:210108-85-3
- Nilgirine
Catalog No.:BCN2100
CAS No.:21009-05-2
- Erythbidin A
Catalog No.:BCN6859
CAS No.:210050-83-2
- LY-900009
Catalog No.:BCC2103
CAS No.:209984-68-9
- LY-411575 isomer 1
Catalog No.:BCC5443
CAS No.:209984-58-7
- LY-411575
Catalog No.:BCC2101
CAS No.:209984-57-6
- Amarogentin
Catalog No.:BCN2661
CAS No.:21018-84-8
- 6-Formyl-1,2,9,10-tetramethoxy-6a,7-dehydroaporphine
Catalog No.:BCN6436
CAS No.:2101836-45-5
- 7-Hydroxycadalene
Catalog No.:BCN7501
CAS No.:2102-75-2
- Gallein
Catalog No.:BCC7563
CAS No.:2103-64-2
- Z-DEVD-FMK
Catalog No.:BCC1137
CAS No.:210344-95-9
- Z-IETD-FMK
Catalog No.:BCC5116
CAS No.:210344-98-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Ac-LEHD-AFC
Catalog No.:BCC2359
CAS No.:210345-03-2
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- Cinnamyl acetate
Catalog No.:BCN4914
CAS No.:21040-45-9
- Spiradine F
Catalog No.:BCN4915
CAS No.:21040-64-2
- Odoratin-7-O-beta-D-glucopyranoside
Catalog No.:BCN8089
CAS No.:210413-47-1
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.[Pubmed:8132559]
J Biol Chem. 1994 Mar 18;269(11):8362-5.
The imino sugar deoxynojirimycin and its alkylated derivatives are inhibitors of the N-linked oligosaccharide processing enzymes alpha-glucosidase I and II. These compounds are glucose analogues and have the potential to inhibit both glucosidases and glucosyltransferases. However, to date there has been no report of deoxynojirimycin or similar analogues inhibiting a mammalian glucosyltransferase. We have investigated the effects of deoxynojirimycin and its alkylated derivatives on the biosynthesis of glycolipids in HL-60 cells. We have found that the N-butyl and N-hexyl derivatives of deoxynojirimycin, but not deoxynojirimycin itself, are novel inhibitors of the glucosyltransferase-catalyzed biosynthesis of glucosylceramide. This results in the inhibition of biosynthesis of all glucosylceramide-based glycosphingolipids. We have investigated the ability of one of these compounds, N-butyldeoxynojirimycin, to offset glucosylceramide accumulation in an in vitro Gaucher's disease model. This compound prevents lysosomal glycolipid storage and offers a novel therapeutic approach for the management of this and other glycolipid storage disorders.